je.st
news
Tag: genomic
Genesus Global Technical Report: Another genomic tool for improving litter size
2018-06-05 02:00:00| ThePigSite - Industry News
Litter size is a very important factor determining sow profitability. A major limitation for increasing litter size is embryonic loss that occurs during the 2nd to 3rd week of gestation (Geisert and Schmitt, 2002, J Anim Sci. 80, E54-E65).
Tags: size
report
global
technical
Genesus global technical report: Selection indexes – Possibilities in the genomic era
2018-05-18 02:00:00| ThePigSite - Industry News
Selection is the process by which we choose animals that become parents of the next generation, and we have been doing this since domestication. The important question is not whether selection is practiced but what is the goal of the selection.
Tags: report
global
technical
selection
Strategies to maximize long-term genetic gain in the genomic era
2018-02-05 01:00:00| ThePigSite - Industry News
Genomic selection (GS) is a new method for improving economic traits in animal populations by utilising information from molecular markers, phenotypes and pedigree.
Tags: era
gain
strategies
genetic
Genomic testing is growing up
2017-02-08 10:55:18| Beef
The beef business is moving from a segmented industry to one thats more united, and information is at the core of that shift. Genomic data is helping that transition.
Tags: up
growing
testing
genomic
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more